Aardvark Therapeutics, Inc. Common Stock (AARD)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on AARD
With Tiblio's Option Bot, you can configure your own wheel strategy including AARD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AARD
- Rev/Share 0.0
- Book/Share 6.3127
- PB 1.2562
- Debt/Equity 0.0047
- CurrentRatio 14.0415
- ROIC -0.297
- MktCap 172056369.0
- FreeCF/Share -1.5222
- PFCF -5.2113
- PE -4.6947
- Debt/Assets 0.0044
- DivYield 0
- ROE -0.7846
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AARD | H.C. Wainwright | -- | Buy | -- | $40 | June 30, 2025 |
| Initiation | AARD | BofA Securities | -- | Buy | -- | $22 | March 10, 2025 |
| Initiation | AARD | Cantor Fitzgerald | -- | Overweight | -- | $50 | March 10, 2025 |
| Initiation | AARD | Morgan Stanley | -- | Overweight | -- | $29 | March 10, 2025 |
| Initiation | AARD | RBC Capital Mkts | -- | Outperform | -- | $21 | March 10, 2025 |
News
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet
AARD
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
About Aardvark Therapeutics, Inc. Common Stock (AARD)
- IPO Date 2025-02-13
- Website https://aardvarktherapeutics.com
- Industry Biotechnology
- CEO Tien-Li Lee
- Employees 22
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.